Artrya Limited has completed the second tranche of its share placement, raising $14.7 million to advance its AI-powered Salix platform for coronary artery disease detection.
- Issued 7.18 million shares at $2.05 each
- Raised approximately $14.7 million before costs
- Funds to support commercialisation of Salix AI platform
- Cleansing notice confirms compliance with Corporations Act
- Placement follows initial tranche announced in September 2025
Capital Raise Completion
Artrya Limited (ASX, AYA), an Australian medical technology company specialising in AI-driven cardiac diagnostics, has successfully completed the second tranche of its share placement. The company issued 7,175,588 fully paid ordinary shares at $2.05 each, raising approximately $14.7 million before costs. This follows the initial tranche announced in early September 2025, marking a significant capital injection aimed at accelerating the commercial rollout of its Salix AI-powered cloud platform.
Advancing AI in Cardiac Care
Artrya’s Salix platform leverages artificial intelligence to provide near real-time, point-of-care assessment and management of coronary artery disease, a leading cause of mortality worldwide. By analysing coronary CT scans to identify key biomarkers, the technology supports clinicians in making more accurate and efficient diagnoses. The fresh capital is expected to bolster regulatory and commercial activities across key international markets, underpinning Artrya’s mission to transform cardiac care through innovative technology.
Regulatory Compliance and Market Implications
Alongside the placement, Artrya issued a cleansing notice in accordance with the Corporations Act 2001, confirming that the share issue was conducted without disclosure under Part 6D.2 and that the company has complied with all relevant disclosure obligations. This transparency reassures investors about the regulatory integrity of the capital raise. However, the announcement does not detail the specific allocation of funds or timelines for commercial milestones, leaving some questions about the immediate impact on operational progress.
Looking Ahead
With the capital secured, Artrya is positioned to intensify its push into the competitive medical technology landscape. The success of the Salix platform in clinical and commercial settings will be critical to validating investor confidence and driving future growth. Market watchers will be keen to see how the company navigates regulatory approvals and expands its footprint internationally in the coming months.
Bottom Line?
Artrya’s latest capital raise sets the stage for a pivotal phase in commercialising AI-driven cardiac diagnostics.
Questions in the middle?
- How will Artrya allocate the $14.7 million to balance regulatory and commercial priorities?
- What are the expected timelines for Salix platform adoption in key international markets?
- How might the share placement impact existing shareholder value and market perception?